Onkologie. 2025:19(1):50-52

Imunoonkologická léčba NSCLC napříč stadii

MUDr. Zuzana Zafarová

Přednášel MUDr. Jaromír Roubec, Ph.D. - Komplexní onkologické centrum Nový Jičín, Plicní oddělení nemocnic Agel, Vítkovice.
Protinádorová imunoterapie významně ovlivnila léčbu karcinomu plic. Již byla publikována a stále probíhá řada klinických studií, které přinášejí nové poznatky a mění praxi léčby zejména nemalobuněčného karcinomu plic (NSCLC), a to ve všech stadiích onemocnění. MUDr. Roubec ve své přednášce na VII. kongresu ČPFS a XXXII. moravskoslezských pneumologických dnech, které proběhly v září 2024 v Ostravě, probral některé z těchto prací, jejichž výsledky vedly ke změně terapeu­tických postupů u NSCLC. Svou prezentaci doplnil kazuistikou starší pacientky se spinocelulárním karcinomem plic stadia III, u níž chemoradioterapie s konsolidační léčbou durvalumabem vedla k celkovému přežití (OS) 2,5 roku.

Accepted: February 27, 2025; Published: March 10, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zafarová Z. Imunoonkologická léčba NSCLC napříč stadii. Onkologie. 2025;19(1):50-52.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 10.3.2026

    References

    1. Forde PM, Spicer J, Lu S, et al. CheckMate 816 Investigators. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985. Go to original source... Go to PubMed...
    2. Modrá kniha České onkologické společnosti (2024). Brno: Masarykův onkologický ústav; 2024.
    3. Provencio Pulla M, Forde PM, Spicer JD, et al. LBA57 - Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression. Annals of Oncology. 2023;34 (suppl_2):S1254-S1335. Go to original source...
    4. Heymach JV, Mitsudomi T, Harpole D, et al. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. Clin Lung Cancer. 2022;23(3):e247-e251. Go to original source... Go to PubMed...
    5. Reck M, Nadal E, Girard N, et al. MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC. Clin Lung Cancer. 2024;25(6):587-593.e3. Go to original source... Go to PubMed...
    6. Felip E, Altorki N, Zhou C, et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol. 2023;34(10):907-919. Go to original source... Go to PubMed...
    7. O'Brien M, Paz-Ares L, Marreaud S, et al. EORTC-1416-LCG/ETOP 8-15 - PEARLS/KEYNOTE-091 Investigators. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274-1286. Go to original source... Go to PubMed...
    8. Antonia SJ, Villegas A, Daniel D, et al; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017;377(20):1919-1929. Go to original source... Go to PubMed...
    9. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40(12):1301-1311. Go to original source... Go to PubMed...
    10. Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350. Go to original source... Go to PubMed...
    11. Peters S, Cho BC, Luft AV, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial. J Thorac Oncol. 2024:S1556-0864(24)02264-0.
    12. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (Check­Mate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.